[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
We used a new chemotherapy regimen for the treatment of 28 consecutive patients with relapsed AML. The regimen consisted of low-dose cytosine arabinocide (ara-C), low-dose aclarubicin and concurrent use of G-CSF (CAG regimen). Twenty four out of 28 patients (86%) achieved complete remission (CR). Median CR duration and median survival were 7 months and 17 months, respectively. Myelosuppression and non-hematological toxicities were apparently low. The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient.